Match!
Marc Scherlinger
University of Bordeaux
Physical therapyLupus erythematosusInfliximabBiosimilarMedicine
32Publications
6H-index
95Citations
What is this?
Publications 34
Newest
We read with great interest the paper from Glintborg and coauthors ‘To switch or not to switch’ reporting biosimilar etanercept switching in Denmark.1 In the Danish Biologic (DANBIO) cohort, patient treated with originator etanercept (Enbrel) were informed of a mandatory switch to SB4. However, the 25 mg pen or a powder-based preparation of original etanercept (OE) were still available. At 1 year after this decision, the authors reported that only 79% of patients had switched to SB4 and 21% rema...
3 CitationsSource
Systemic lupus erythematosus (SLE) is a systemic and potentially fatal autoimmune disease. SLE pathophysiology is complex and involves the interplay between the innate and adaptive immune systems, with a particularly significant role for type I interferons. Recently, the participation of other actors such as platelets and IgE has been described in SLE. On the one hand, platelets activated by different stimuli (antiphospholipid antibodies, immune complexes…) participate in immune dysregulation th...
5 CitationsSource
#1Marc ScherlingerH-Index: 6
#2Philippe MertzH-Index: 2
Last. Anne-Sophie KorganowH-Index: 18
view all 19 authors...
Source
#1Vincent Germain (University of Bordeaux)H-Index: 2
#2Marc ScherlingerH-Index: 6
Last. Thierry Schaeverbeke (University of Bordeaux)H-Index: 12
view all 4 authors...
To date, all available data regarding the switch from bio-originator to its biosimilar are reassuring, and the switch has been recommended as a shared patient–physician decision in recent consensus-based recommendations.1 In particular, the Norway's infliximab switching study (NOR-SWITCH study), a 52-week randomised double-blind trial, strongly supports the efficacy and safety of the switch from originator infliximab (OI) to its biosimilar CT-P13 in patients with a stable disease.2 However, long...
2 CitationsSource
#1Imen Ben Hassine (University of Paris)H-Index: 1
#2Christopher Rein (Metz)H-Index: 1
Last. Patrice CacoubH-Index: 72
view all 19 authors...
Abstract Objective: To describe the clinical presentation, distribution of lesions, treatment, and outcomes of osseous sarcoidosis. Methods: A French retrospective multicenter study of patients with biopsy-proven sarcoidosis analyzed patients with 1) a biopsy-proven granuloma without caseous necrosis, and either 2) osseous clinical manifestations, or 3) abnormal osseous imaging. Sarcoidosis patients with osseous involvement (cases) were compared with 264 age- and sex-matched sarcoidosis patients...
1 CitationsSource
#1Marc ScherlingerH-Index: 6
#2C Carcaud (University of Bordeaux)H-Index: 1
Last. Christophe RichezH-Index: 23
view all 10 authors...
Many targeted therapies have been developed for systemic lupus erythematosus (SLE) in recent years and almost all have failed to meet their predesigned endpoints.1 Among these therapies, rituximab (RTX) has reported good results in several open-label studies,2 3 but failed to meet its primary endpoints in two randomised controlled trials (RCTs), EXPLORER and LUNAR.4 5 Among the proposed explanations for these failures, the primary outcome criteria’s lack of sensitivity has been suggested.6 The a...
3 CitationsSource
#1Antoine Grillon (UDS: University of Strasbourg)H-Index: 4
#2Marc ScherlingerH-Index: 6
Last. Benoît Jaulhac (UDS: University of Strasbourg)H-Index: 24
view all 29 authors...
Abstract Objectives To describe the clinical and microbiological characteristics and outcomes after antibiotic treatment of a national cohort of patients with Lyme arthritis confirmed by PCR testing on synovial fluid and by serology, when available. Methods Using the French National Reference Center for Borrelia database, patients with a positive PCR on synovial fluid for Borrelia were identified. Patient clinical and biological characteristics were reviewed from patient records. Long-term outco...
3 CitationsSource
Source
#1Marc Scherlinger (University of Bordeaux)H-Index: 6
#2Vincent Germain (University of Bordeaux)H-Index: 2
Last. Fédération hospitalo-universitaire Acronim (University of Bordeaux)
view all 10 authors...
Resume Objectifs Etudier l’acceptabilite et le taux de maintien de l’infliximab biosimilaire CT-P13 (Inflectra©) apres switch a partir de l’infliximab original (IO) chez des patients atteints de rhumatismes inflammatoires. Methodes Il a ete propose a des patients atteints de polyarthrite rhumatoide (PR), de spondylarthrite ankylosante (SA) ou de rhumatisme psoriasique (RhPso) controles sous IO, un switch pour le CT-P13 en poursuivant le meme schema therapeutique. Une cohorte prospective de patie...
Source
In their correspondence, Cantini and Benucci1 express their concern about the lack of real-life data supporting the switch from originator to biosimilar biological disease-modifying antirheumatic drugs, as recommended in the recently issued consensus-based recommendations.2 They argue that the Danish Nationwide Biologic (DANBIO) registry reporting real-life data showed a lower than expected retention rate after the switch to biosimilar infliximab (bio-IFX) and etanercept.3 4 Concerning bio-IFX, ...
2 CitationsSource
1234